New immunomodulating drugs in treating moderate to severe psoriasis
Favorable effects on skin lesions and quality of life in patients with moderate to severe plaque psoriasis have been shown after treatment with infliximab, etanercept and efalizumab for 3 to 6 months (strong scientific evidence). The scientific evidence is insufficient to assess the long-term effect...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Stockholm, Sweden
SBU-Swedish Council on Health Technology Assessment
[2006], 2006
|
| Series: | SBU alert report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Favorable effects on skin lesions and quality of life in patients with moderate to severe plaque psoriasis have been shown after treatment with infliximab, etanercept and efalizumab for 3 to 6 months (strong scientific evidence). The scientific evidence is insufficient to assess the long-term effects of the 3 drugs, as well as the potential, uncommon and long-term side effects. Treatment costs per quality-adjusted life-year are high, or very high, even when the drugs are used within the approved indications (patients who respond inadequately to treatment, or who cannot receive established therapy for other reasons). Utilization beyond the scope of the approved indications would generate extremely high costs |
|---|---|
| Physical Description: | 1 PDF file (3 pages) |